{"id":192603,"date":"2022-01-14T18:26:55","date_gmt":"2022-01-14T18:26:55","guid":{"rendered":"https:\/\/www.atvtoday.co.uk\/?p=192603"},"modified":"2022-01-14T18:26:55","modified_gmt":"2022-01-14T18:26:55","slug":"192603-health","status":"publish","type":"post","link":"https:\/\/atvtoday.co.uk\/newsarchive\/2022\/01\/14\/192603-health\/","title":{"rendered":"WHO recommends two new drugs to treat COVID\u221219"},"content":{"rendered":"<h5>The drugs add to an expanding toolbox for COVID-19 treatment.<\/h5>\n<p><!--more--><\/p>\n<p style=\"text-align: justify;\">The <em>World Health Organisation<\/em> has recommended two new drugs for COVID-19, providing yet more options for treating the disease. The extent to which these medicines will save lives depends on how widely available and affordable they will be.<\/p>\n<p style=\"text-align: justify;\">The first drug, <em>Baricitinib<\/em>, is strongly recommended for patients with severe or critical COVID-19. It is part of a class of drugs called Janus kinase inhibitors that suppress the overstimulation of the immune system. WHO recommends that it be given with corticosteroids.<em> Baricitinib<\/em> is an oral drug, used in the treatment of rheumatoid arthritis. It provides an alternative to other arthritis drugs called Interleukin-6 receptor blockers,\u00a0recommended\u00a0by WHO in July 2021.<\/p>\n<p style=\"text-align: justify;\">WHO has also conditionally recommended the use of a monoclonal antibody drug, <em>Sotrovimab<\/em>, for treating mild or moderate COVID-19 in patients who are at high risk of hospitalization. This includes patients who are older, immunocompromised, have underlying conditions like diabetes, hypertension, and obesity, and those unvaccinated.<\/p>\n<p style=\"text-align: justify;\"><em>Sotrovimab<\/em> is an alternative to <em>Casirivimab-Imdevimab<\/em>, a monoclonal antibody cocktail\u00a0recommended\u00a0by WHO in September 2021. Studies are ongoing on the effectiveness of monoclonal antibodies against Omicron but early laboratory studies show that <em>Sotrovimab<\/em> retains its activity.<\/p>\n<p style=\"text-align: justify;\">The panel of experts developing the guidelines also looked at two other drugs for severe and critical COVID-19: ruxolitinib and tofacitinib. Given their uncertain effects, WHO made a conditional recommendation against their use. Today\u2019s recommendations, forming the eighth update of WHO\u2019s living guidelines on\u00a0<a href=\"https:\/\/www.who.int\/teams\/health-care-readiness-clinical-unit\/covid-19\/therapeutics\" target=\"_blank\" rel=\"noopener\">therapeutics and COVID-19<\/a>, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19.<\/p>\n<p style=\"text-align: justify;\">WHO is in discussions with manufacturers to secure global supply capacity and equitable and sustainable access to the newly recommended therapeutics. The Access to COVID-19 Tools Accelerator (ACT-A) Therapeutics pillar has been engaging with pharmaceutical companies to seek comprehensive access plans for low- and middle-income countries, so that these treatments can be rapidly deployed everywhere, not just in rich countries. The ACT-A is also looking to expand licensing scope to make the products more affordable.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The drugs add to an expanding toolbox for COVID-19 treatment.<\/p>\n","protected":false},"author":1,"featured_media":192606,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"pagelayer_contact_templates":[],"_pagelayer_content":"","footnotes":""},"categories":[39],"tags":[],"class_list":["post-192603","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lifestyle"],"_links":{"self":[{"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/posts\/192603","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/comments?post=192603"}],"version-history":[{"count":0,"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/posts\/192603\/revisions"}],"wp:attachment":[{"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/media?parent=192603"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/categories?post=192603"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/atvtoday.co.uk\/newsarchive\/wp-json\/wp\/v2\/tags?post=192603"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}